---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-024838"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T22:58:10.081043+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aligos Therapeutics secures $105M private placement to fund Phase 2 hepatitis B study

## Summary
- Gross proceeds ~$105M from sale of 2.1M shares, pre-funded warrants (1.9M shares), and warrants (2.0M shares); closing expected Feb 13, 2025.
- Combined price $26.0825 per share/warrant; warrants exercisable at $26.02, expire Feb 13, 2032; pre-funded warrants at $0.0001.
- Net proceeds to fund ALG-000184 Phase 2 study in chronic hepatitis B; cash runway extended into H2 2026.
- Placement led by life sciences investor; Jefferies and Piper Sandler as agents; lead investor gets board nomination rights.
- Company to file resale registration statement within 45 days; securities sold in private placement exempt from registration.

## SEC filing metadata
- accession: 0001193125-25-024838
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000119312525024838/0001193125-25-024838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000119312525024838/d901857d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-024838
- JSON: https://secwatch.observer/filing/0001193125-25-024838.json
- Plain text: https://secwatch.observer/filing/0001193125-25-024838.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.